On November 11, 2026 Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, reported that Leonard Mazur, Chairman and Chief Executive Officer, will participate in the Jefferies London Healthcare Conference, taking place November 16–19, 2026, in London, United Kingdom.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Mazur will provide an overview of the Company’s business and recent developments, including the ongoing commercialization of LYMPHIR (denileukin diftitox-cxdl) by the Company’s majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR).

Conference Details:

Conference: Jefferies London Healthcare Conference
Dates: November 16–19, 2026
Location: Waldorf Hilton & ME Hotels, London, United Kingdom
Format: one-on-one meetings
One-on-one meetings with management may be scheduled by contacting a conference representative or the Company’s investor relations team.

(Press release, Citius Pharmaceuticals, NOV 11, 2026, View Source [SID1234674615])